Back to search results

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Hypertrophic Cardiomyopathy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California, United States

    Contact: Study coordinator (Matt Fahey) · mjfahey@health.ucsd.edu · 858-534-3798

  • University of California San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Emma Reagan) · Emma.reagan@ucsf.edu · 415-514-7280

  • Emory University, Atlanta, Georgia, United States

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

  • Mayo Clinic, Rochester, Minnesota, United States

    Contact: Study coordinator (Sierra Slade) · Slade.Sierra@mayo.edu · 507-422-5433

  • The Christ Hospital Physicians - The Ohio Heart and Vascular Center, Cincinnati, Ohio, United States

  • Cleveland Clinic, Cleveland, Ohio, United States

    Contact: Study coordinator (Rachael Landis) · LANDISR@ccf.org · 216-444-3650

  • Oregon Health & Science University, Portland, Oregon, United States

  • Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • Houston Methodist Hospital, Houston, Texas, United States

    Contact: Study coordinator (Jennifer Garrett) · jmgarrett@houstonmethodist.org · 281-222-9983
View source on ClinicalTrials.gov(opens in a new tab)